Previous 10 | Next 10 |
PALO ALTO, Calif. , May 8, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will host a business highlights webcast on Tuesday...
Market Pulse The COVID-19 pandemic has thrust biopharma to the forefront in the search for a solution. And biotechs will remain at the investing forefront as the quest for anti-viral treatments and vaccines continues to be the race for the holy grail that can restore economic activity around...
Keeping tabs on the quarterly activity of billionaire superinvestors can be a great way to unearth hidden gems, or perhaps avoid potential potholes. Billionaires, after all, are rich for a reason. When it comes to the complex but rewarding area of healthcare, Baker Brothers Advisors, a hedge fun...
The most important thing is to survive the outbreak. Thereafter, for our portfolio to survive too so it can do well when the situation is favorable. Market Pulse The stock market remains unsettled and vulnerable to sharp declines. Over the last two weeks, the market has forcefully steppe...
Gainers: NLS +38.7% . BIG +15.4% . GRIN +16.6%. KPTI +14.1% . PLUS +13.4% . More news on: Nautilus, Inc., Big Lots, Inc., Grindrod Shipping Holdings Ltd., Stocks on the move, , Read more ...
PALO ALTO, Calif. , April 2, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Charles Bancroft to its board of director...
Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Outperform rating and $54 (88% upside) price target at BMO. More news on: Apellis Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., HEXO Corp., Healthcare stocks news, Stocks on the move, , Read more ...
For all those who missed the train in 2019, the coronavirus pandemic has presented another chance to pick up Kodiak Sciences ( KOD ) stock. Let us see, what makes the company a solid buy at these share price levels. Company overview Founded in 2009, Kodiak Sciences is a clinical-stage bi...
I am constantly looking to provide valuable information to my readers on how to outperform the market while taking few risks. A very strong strategy to outperform the market is following insider purchases, as literature has proven that this strategy could beat the market by as much as 24.20% p...
Market Pulse This week all the major indexes made new lows. The market continues to be under stress and this is not the final low. Biotechs were one of the few industry groups that didn't make a new low this week. A respite from non-stop selling will come from the economic stimulus package w...
News, Short Squeeze, Breakout and More Instantly...
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences PR Newswire PALO ALTO, Calif. , May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transfor...
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results PR Newswire PALO ALTO, Calif. , May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the qu...
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy PR Newswire PALO ALTO, Calif. , May 13, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to r...